MRC Technology and NYU School of Medicine have signed an agreement to develop an antibody for the prevention of inflammatory osteolysis (bone breakdown).
23 April 2015
MRC Technology has appointed Andrew Mercieca as its Finance Director from 1 April 2015. Andrew joined the company as Interim Finance Director in August 2014.
17 April 2015
MRC Technology announced it has negotiated a licence for ultrastable gold supports developed at the MRCLaboratory of Molecular Biology, with Quantifoil Micro Tools GmbH (Quantifoil). Under this licence, Quantifoil will manufacture and market the gold supports (UltrAuFoil™).
30 March 2015
Immunotherapy, which uses the body’s own defence mechanism, is at long last becoming accepted as a frontline treatment for cancer, taking its place alongside conventional chemotherapy and radiation-based treatments.
27 March 2015
MRC Technology (MRCT) and Cyclofluidic Ltd have announced the successful completion of their collaboration to identify and optimise drug-like molecules with activity against hepsin, a serine protease known to be overexpressed in prostate, breast, kidney, and ovarian cancers and an important target in the fight against cancer.
23 March 2015
The basic idea behind immunotherapy for cancer is to stimulate the body’s immune system to attack a cancer rather than the drug directly targeting the diseased cells. Antibodies such as Herceptin, for example, direct a specific attack on cancerous breast cells but a new generation of antibody drugs can also mediate this immunotherapy approach.
10 March 2015
‘Call for targets’ launched to find new therapeutic concepts for treatment of respiratory disease, including conditions such as allergy, acute respiratory distress syndrome (ARDS), asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, and cystic fibrosis.
2 March 2015
Dr Edward Bliss appointed in new role of General Counsel and Company Secretary.
3 February 2015
‘A novel high throughput assay to identify activators of the two-pore domain potassium channel TRESK’ and ‘Identification of small molecule melanocortin 2 receptor antagonists as potential therapeutics for Cushing’s disease’.
19 January 2015
MRC Technology and charity partners launched a consortium to uncover promising drugs in pharma libraries that could be developed to treat brain diseases.
13 January 2015